Mayo Clinic Licenses Expression Pathology IP | GenomeWeb

NEW YORK (GenomeWeb News) – Mayo Clinic has acquired a non-exclusive license to Expression Pathology's patent for use in diagnosing systemic amyloidosis in formalin-fixed tissue.

Expression Pathology said today that Mayo Clinic will use the Liquid Tissue patent in a test using mass spectrometric analysis of formalin-fixed paraffin-embedded tissue. Mayo Clinic will offer the test worldwide through its Mayo Medical Laboratories reference laboratory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.